Growth Hormone and IGF-I Axis: A Key Player in Alzheimer's Disease?
Background
Alzheimer's disease (AD) is a devastating neurodegenerative disorder characterized by progressive memory loss and cognitive decline, with no effective cure. The Growth Hormone (GH) and Insulin-like Growth Factor-I (IGF-I) axis is a crucial endocrine system involved in metabolism, growth, and neuroprotection. While dysregulation of this axis is known to impact brain health, the specific role and implications of GH/IGF-I signaling in the pathogenesis and progression of AD remained an area requiring comprehensive synthesis.
Why It Matters
This synthesis highlights the GH/IGF-I axis as a critical endocrine regulator in Alzheimer's disease, offering a novel perspective on its pathogenesis. Understanding this intricate relationship could pave the way for innovative diagnostic biomarkers and therapeutic strategies. Targeting the GH/IGF-I pathway, for instance through GH secretagogues or IGF-I mimetics, could represent a promising avenue for future clinical interventions to slow or prevent AD progression. Further research, including Phase II human trials, is warranted to evaluate the efficacy and safety of modulating this axis in AD patients.